Department of Gastroenterology and Hepatology, Digestive Disease Institute, The Cleveland Clinic, Cleveland, Ohio 44195, USA.
JPEN J Parenter Enteral Nutr. 2013 Sep;37(5):683-8. doi: 10.1177/0148607112471860. Epub 2013 Jan 14.
Intra-abdominal desmoid tumors (IADTs) are a common complication of familial adenomatous polyposis (FAP). Treatment is not standardized for advanced disease. Medical and surgical treatments may be ineffective in preventing complications, which can cause intestinal failure. Home parenteral nutrition (HPN) can be a life-saving treatment in these patients. The aim of this study was to investigate the association with HPN in FAP-IADTs.
A retrospective review of FAP patients with IADTs at the Cleveland Clinic (CC) between 1980 and 2009 was performed. Patients and tumor characteristics were retrieved from the CC Jagelman Registry for Inherited Neoplasms and CC HPN database. Inclusion criteria were FAP-IADTs and 6-month follow up at CC. Exclusion criteria were <6-month follow-up, lack of 3-dimensional lesion or sheet desmoid, and/or incomplete medical records. Kaplan-Meier curves were analyzed for HPN and non-HPN groups.
One hundred fifty-four patients were included and divided into 2 groups: HPN (n = 41, 26.6%) and non-HPN (n = 113, 73.4%). The HPN group was more likely to have advanced-stage disease and significantly higher incidence of chronic abdominal pain, narcotic dependency, bowel obstruction, ureteral obstruction, deep vein thrombosis, pulmonary embolism, fistulae, and sepsis (P < .05). The need for HPN represented a strong predictor of mortality (5-year survival HPN = 72% vs non-HPN = 95%), but duration of HPN did not affect mortality.
HPN, although a life-saving treatment, is an independent poor prognostic factor associated with high morbidity and mortality.
腹内型纤维瘤病(IADTs)是家族性腺瘤性息肉病(FAP)的常见并发症。对于晚期疾病,尚无标准化的治疗方法。医疗和手术治疗可能无法预防会导致肠衰竭的并发症。家庭肠外营养(HPN)可能是这些患者的救命治疗方法。本研究旨在探讨与 FAP-IADTs 中 HPN 的关联。
对 1980 年至 2009 年在克利夫兰诊所(CC)接受 IADTs 的 FAP 患者进行了回顾性研究。从 CC Jagelman 遗传性肿瘤登记处和 CC HPN 数据库中检索患者和肿瘤特征。纳入标准为 FAP-IADTs 和在 CC 进行 6 个月随访。排除标准为<6 个月随访、缺乏 3 维病变或片状纤维瘤和/或病历不完整。对 HPN 和非 HPN 组进行 Kaplan-Meier 曲线分析。
共纳入 154 例患者,分为 2 组:HPN(n = 41,26.6%)和非 HPN(n = 113,73.4%)。HPN 组更可能患有晚期疾病,且慢性腹痛、阿片类药物依赖、肠梗阻、输尿管梗阻、深静脉血栓形成、肺栓塞、瘘管和脓毒症的发生率显著更高(P<0.05)。需要 HPN 是死亡率的强预测因素(5 年生存率 HPN = 72%vs 非 HPN = 95%),但 HPN 的持续时间并不影响死亡率。
HPN 虽然是一种救命治疗方法,但也是一个独立的预后不良因素,与高发病率和死亡率相关。